Diabetes is one of the leading chronic conditions worldwide, and breast cancer is the most prevalent cancer in women worldwide. The linkage between diabetes and its ability to increase the risk of breast cancer should always be analyzed in patients. This review focuses on the impact of antihyperglycemic therapy in breast cancer patients. Patients with diabetes have a higher risk of developing cancer than the general population. Moreover, diabetes patients have a higher incidence and mortality of breast cancer. In this review, we describe the influence of antidiabetic drugs from insulin and metformin to the current and emerging therapies, incretins and SGLT-2 inhibitors, on breast cancer prognosis. We also emphasize the role of obesity and the metastasis process in breast cancer patients who are treated with antidiabetic drugs.
糖尿病是全球主要慢性疾病之一，而乳腺癌是全球女性最常见的恶性肿瘤。临床实践中应始终关注糖尿病与乳腺癌风险增加之间的关联性。本综述聚焦于降糖治疗对乳腺癌患者的影响。糖尿病患者较普通人群具有更高的患癌风险，且乳腺癌发病率和死亡率在糖尿病患者中显著升高。本文系统阐述了从胰岛素、二甲双胍到当前新型疗法（肠促胰岛素类药物及SGLT-2抑制剂）在内的各类降糖药物对乳腺癌预后的影响，同时重点探讨了接受降糖治疗的乳腺癌患者中肥胖及转移过程所起的作用。
肿瘤(癌症)患者之家